Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | GLA | P06280 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252583 | 0.90 | ADORA1 (0.69) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6254531 | 0.85 | ADORA1 (0.54) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6256893 | 0.81 | ADORA1 (0.62) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6249884 | 0.78 | ADORA1 (0.57) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6253670 | 0.76 | ADORA1 (0.67) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6255586 | 0.75 | ADORA1 (0.58) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL6253365 | 0.75 | ADORA1 (0.66) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL6252357 | 0.74 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL6255188 | 0.72 | ADORA2A (0.69) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL6251967 | 0.72 | ADORA1 (0.76) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569645-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569932-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | US | disclosed |
| WO-2004055015-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054505-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP2K2, MAP3K2 | ADORA1 3401/4885ADORA2A 1929/4885ADORA2B 2324/4885 |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | MAP4K2, MAP3K20, MAPKAPK2 | ADORA1 1798/4885ADORA2A 877/4885ADORA2B 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.